Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.

Dolusić E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B, Masereel B, Wouters J, Frédérick R.

J Med Chem. 2011 Aug 11;54(15):5320-34. doi: 10.1021/jm2006782. Epub 2011 Jul 18.

PMID:
21726069
2.

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. doi: 10.1073/pnas.1113873109. Epub 2012 Jan 30.

3.

The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat.

Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ.

Biochem Pharmacol. 1995 May 17;49(10):1435-42.

PMID:
7539265
4.

Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase.

Pantouris G, Mowat CG.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):28-31. doi: 10.1016/j.bbrc.2013.11.037. Epub 2013 Nov 19.

PMID:
24269239
5.

Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives.

Eguchi N, Watanabe Y, Kawanishi K, Hashimoto Y, Hayaishi O.

Arch Biochem Biophys. 1984 Aug 1;232(2):602-9.

PMID:
6431906
6.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
7.

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ.

Nat Med. 2003 Oct;9(10):1269-74. Epub 2003 Sep 21.

PMID:
14502282
8.
9.

Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti.

Suzuki S, Toné S, Takikawa O, Kubo T, Kohno I, Minatogawa Y.

Biochem J. 2001 Apr 15;355(Pt 2):425-9.

10.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC.

Nat Med. 2005 Mar;11(3):312-9. Epub 2005 Feb 13.

PMID:
15711557
11.

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).

Dolušić E, Frédérick R.

Expert Opin Ther Pat. 2013 Oct;23(10):1367-81. doi: 10.1517/13543776.2013.827662. Epub 2013 Aug 30. Review.

PMID:
23992582
12.

Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.

Schmidt SK, Müller A, Heseler K, Woite C, Spekker K, MacKenzie CR, Däubener W.

Eur J Immunol. 2009 Oct;39(10):2755-64. doi: 10.1002/eji.200939535.

13.

[A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].

Van den Eynde B.

Bull Mem Acad R Med Belg. 2003;158(7-9):356-63; discussion 364-5. French.

PMID:
15132006
14.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
15.

Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.

Austin CJ, Rendina LM.

Drug Discov Today. 2015 May;20(5):609-17. doi: 10.1016/j.drudis.2014.11.007. Epub 2014 Dec 3. Review.

PMID:
25478733
16.

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH.

Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Review.

PMID:
18282734
17.

Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.

Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, Pusch S, Opitz CA, Blaes J, von Deimling A, Wick W, Platten M.

Glia. 2015 Jan;63(1):78-90. doi: 10.1002/glia.22734. Epub 2014 Aug 5.

PMID:
25132599
18.

High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.

Seegers N, van Doornmalen AM, Uitdehaag JC, de Man J, Buijsman RC, Zaman GJ.

J Biomol Screen. 2014 Oct;19(9):1266-74. doi: 10.1177/1087057114536616. Epub 2014 May 27.

PMID:
24870017
19.

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.

Liu X, Newton RC, Friedman SM, Scherle PA.

Curr Cancer Drug Targets. 2009 Dec;9(8):938-52. Review.

PMID:
20025603
20.

Purification and biochemical characterization of a recombinant Anopheles gambiae tryptophan 2,3-dioxygenase expressed in Escherichia coli.

Paglino A, Lombardo F, Arcà B, Rizzi M, Rossi F.

Insect Biochem Mol Biol. 2008 Sep;38(9):871-6. doi: 10.1016/j.ibmb.2008.05.011. Epub 2008 Jul 17.

PMID:
18687401
Items per page

Supplemental Content

Write to the Help Desk